Related Experiment Video
Updated: May 8, 2026

An Adoptive Transfer Model of Rheumatoid Arthritis in Mice
Published on: June 6, 2025
Activin A: a potential therapeutic target for characterizing and stopping joint pain early in rheumatoid arthritis
1Department of Orthopedic Surgery, The Second Affiliated Hospital School of Medicine, Xi'an Jiaotong University, #157 Xi-wu Road Xi'an, Shaanxi, 710004, China, dfei2010@gmail.com.
Abstract:
It is common for rheumatoid arthritis patients to suffer from persistent joint pain for decades during their lifetime. Activin A, a member of the transforming growth factor β superfamily, which plays a role in the very early phase of inflammatory processes, can also induce pain behaviors. In view of the contribution of synovial inflammation to the progression of rheumatoid arthritis, here we present the hypothesis that activin A may be a potential therapeutic target, serving as a marker for joint pain in which inflammatory processes are involved and as a target for early intervention.
Related Concept Videos
The JAK-STAT Signaling Pathway
Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF
Targets for Drug Action: Overview
Receptors are either membrane-spanning or intracellular proteins, which upon binding a ligand, get activated and transmit the signal downstream to elicit a response. Drugs bind receptors, either mimicking the action of endogenous ligands or blocking the receptor activity to bring about a modified response. Nearly 35% of approved drugs target the G...
Chronic Inflammation: Introduction